Exagen (XGN)
(Delayed Data from NSDQ)
$1.88 USD
-0.01 (-0.53%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.89 +0.01 (0.53%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum B VGM
Brokerage Reports
Exagen Inc. [XGN]
Reports for Purchase
Showing records 21 - 36 ( 36 total )
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Recovery in Dx Testing with Larger Menu in 2023
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Strong Quarter, Strong Outlook, Momentum Building
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
The Best Type of ''Guide Down''; Building Visibility Warrants Higher Multiple
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Worth More with Less SIMPONI; Diagnostic Sum-of-Parts; Raising Target Price to $33
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Molecular Diagnostic Market Improves in 3Q; S-3 Filing Potentially Addresses 70% Valuation Discount
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Initiating Coverage at Overweight; Micro-Cap Discount for Autoimmune Molecular Dx Leader
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department